LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, today announced Q1 2011 financial
results. The Company announced record quarterly sales of $14.6mm
and an adjusted operating profit of $1.4 million. Separately, the
Company announced a dividend of $0.02 per share. The Company also
gave Q2 2011 and full-year 2011 guidance.
Q1 2011 sales increased 6% (+4% organic) versus Q1 2010. Sales
in the Americas grew 12%, while international sales decreased 3%.
By product category, Vascular grew 13% while Endovascular decreased
12% as the Company de-emphasized its TAArget/Unifit stent grafts.
Excluding TAArget/Unifit, Q1 2011 sales growth was 9%. Vascular
accounted for 74% of revenues in Q1 2011 while the Americas
accounted for 62%.
The Company reported a gross margin of 69.5% in Q1 2011, versus
74.7% in Q1 2010. The decrease was largely due to costs
related to the relocation of the Company's polyester graft
manufacturing from Italy to Burlington.
Excluding restructuring, impairment and start-up costs related
to the transition of manufacturing from Italy to Burlington, Q1
2011 operating income was $1.4mm. Reported Q1 2011 operating
loss was $30,000, versus an operating profit of $1.3mm in the year
earlier period. The Q1 2011 reported results were reduced by
$1.0mm of largely non-cash charges related to the closure of the
Italian factory, and $0.4mm of manufacturing start-up costs. Net
income in Q1 2011 was $64,000, or $0.00 per diluted share, versus
$1.0mm, or $0.06 per diluted share, in Q1 2010.
George W. LeMaitre, Chairman and CEO, said, "In Q1 normalized
operating income grew to $1.4mm due to the 6% sales increase and
tight expense control. We are proceeding with several
initiatives to 1) focus on our faster growing vascular business, 2)
consolidate our Italian manufacturing facility, and 3) establish a
direct presence in Spain and Denmark. We will largely complete
these initiatives in Q2. Associated charges should then begin to
recede, resulting in a more profitable entity in the back half of
the year."
Q1 2011 operating expenses were $10.2mm. Excluding special
charges, operating expenses in Q1 2011 were $9.1mm, nearly flat
with the prior year period due to reduced R&D costs as well as
general belt-tightening. As of March 31, 2011 the Company had
232 employees, down from 255 at year-end 2010.
Cash and marketable securities as of March 31, 2011 was $19.1mm,
down from $22.6mm at December 31, 2010. The decline was mainly due
to the payment of 2010 annual bonuses and commissions, the build
out of our new Burlington facility, payments related to the Italian
closure, and share repurchases.
Sales and marketing expenses increased 2% in Q1 2011 to
$5.0mm. The Company ended Q1 2011 with 66 sales
representatives, up from 61 at the end of Q1 2010.
General and administrative expenses increased 9% in Q1 2011 to
$2.8mm. Increases were largely due to additional European
country managers, as well as amortization of the intangible assets
acquired in our Lifespan acquisition.
R&D expenses decreased 17% to $1.3mm in Q1 2011, a result of
decreased product development and decreased regulatory and clinical
affairs costs. In Q1 2011, the Company submitted regulatory
approvals for its redesigned UnBalloon in the U.S and Europe.
Quarterly Dividend
The Company's Board of Directors approved the payment of a
quarterly cash dividend on the Company's common stock of $0.02 per
share, with payment to be made on June 6, 2011 to shareholders of
record at the close of business on May 20, 2011. Future
declarations of quarterly dividends and the establishment of future
record and payment dates are subject to the final determination of
the Company's Board of Directors.
Business Outlook
The Company expects Q2 2011 sales of $15.5mm (+9% versus 2010),
and reported operating income of $1.1mm. This guidance
implies a 7% reported operating margin for Q2 2011. Q2 2011
operating income guidance is after an estimated $0.7mm in charges
largely related to the distributor buyouts in Spain and
Denmark.
The Company maintained its full-year 2011 sales guidance of
$62.0mm (+11% versus 2010), and reported operating income guidance
of $6.0mm. This guidance implies a 10% reported operating
margin for 2011. Full-year operating income guidance is after
charges associated with the various restructuring initiatives.
Except as otherwise stated, all guidance amounts exclude the
effects of future acquisitions, foreign exchange rate changes,
distributor terminations and factory consolidations.
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. EDT today
to review the Company's financial results and discuss its business
outlook for the remainder of the year. The conference call
will be broadcast live over the Internet. Individuals who are
interested in listening to the webcast should log on to the
Company's website at www.lemaitre.com/investor. The conference call
may also be accessed by dialing 866-783-2146 (+1-857-350-1605 for
international callers), using passcode 55901779. For individuals
unable to join the live conference call, a replay will be available
on the Company's website.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of
peripheral vascular disease, a condition that affects more than 20
million people worldwide. The Company develops, manufactures
and markets disposable and implantable vascular devices to address
the needs of its core customer, the vascular surgeon.
Well-known to vascular surgeons, the Company's diversified
product portfolio consists of brand name devices used in arteries
and veins outside of the heart, including the Expandable LeMaitre
Valvulotome and the Pruitt F3 Carotid Shunt.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc. This press release
contains other trademarks and trade names of the Company.
For more information about the Company, please visit
http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to properly
understand the Company's short-term and long-term financial trends,
investors may wish to consider the impact of certain non-cash or
non-recurring or infrequently-occurring items, when used as a
supplement to financial performance measures in accordance with
GAAP. These items result from facts and circumstances that
vary in frequency and/or impact on continuing operations. In
addition, management uses results of operations before such items
to evaluate the operational performance of the Company and as a
basis for strategic planning. Investors should consider these
non-GAAP measures in addition to, and not as a substitute for,
financial performance measures in accordance with GAAP. In
addition to the description provided below, reconciliation of GAAP
to non-GAAP results is provided in the financial statement tables
included in this press release.
In this press release, the Company has reported a non-GAAP
financial measure, adjusted operating income, which excludes
certain expenses related to the closure of its Italian
manufacturing facility and relocation of the associated
manufacturing operations to its Burlington, Massachusetts
headquarters. During Q1 2011, the Company incurred $0.4mm of
costs related to the start-up of the associated manufacturing in
Burlington, Massachusetts, all of which was charged to cost of
sales, $0.7mm in non-cash write-offs due to the abandonment of the
Italian building lease and $0.3mm of equipment transfer costs, all
of which was charged to restructuring, and $0.1 million of
unrelated impairment of intangible assets. The Company did not
incur any such charges in Q1 2010.
Also, this press release includes sales growth excluding
specific product lines, which the Company refers to as sales growth
excluding TAArget/Unifit. The Company continues to de-emphasize its
TAArget/Unfit stent grafts, which declined by $0.4mm in the three
months ended March 31, 2011 as compared to the comparable period in
the prior year.
In addition, this press release includes sales growth after
adjusting for foreign exchange, business development transactions,
and other events. The Company refers to this as "organic" sales
growth. The Company analyzes net sales on a constant currency
basis net of acquisitions and other non-recurring events to better
measure the comparability of results between periods. Because
changes in foreign currency exchange rates have a non-operating
impact on net sales, and acquisitions, product discontinuations,
and other strategic transactions are episodic in nature and highly
variable in sales impact, the Company believes that evaluating
growth in sales on a constant currency basis net of such
transactions provides an additional and meaningful assessment of
sales to both management and the Company's investors. During Q2
2010, the Company divested the OptiLock Implantable Port and
discontinued sales of the aSpire Stent, and in Q4 2010, the Company
acquired its LifeSpan Vascular Graft business.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding the Company's
business that are not historical facts may be "forward-looking
statements" that involve risks and
uncertainties. Specifically, statements regarding the
Company's financial and operational guidance, its plans to
transition polyester graft manufacturing from Brindisi, Italy to
Burlington, Massachusetts, and its plans to begin direct sales in
Spain and Denmark, are forward-looking, involving risks and
uncertainties. The Company's current quarterly financial
results, as discussed in this release, are preliminary and
unaudited, and subject to adjustment. Forward-looking
statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties that could
cause actual results to differ from the results
predicted. These risks and uncertainties include, but are not
limited to, the risk that the Company is not successful in
transitioning to a direct selling model in Spain and Denmark; the
risk that the Company experiences production delays or quality
difficulties in the consolidation of its manufacturing operations;
the risk that the Company does not generate sufficient operating
scale to maintain or increase profitability; risks related to
product demand and market acceptance of the Company's products; the
possibility that the Company's new products may fail to provide the
desired safety and efficacy or may not be accepted by the market
for other reasons; the significant competition the Company faces
from other companies, technologies, and alternative medical
procedures; the risk that the Company may fail to expand its
product offerings through internal development or acquisition; the
general uncertainty related to seeking regulatory approvals for the
Company's products; and other risks and uncertainties included
under the heading "Risk Factors" in our most recent Annual Report
on Form 10-K, as updated by our subsequent filings with the SEC,
all of which are available on the Company's investor relations
website at http://www.lemaitre.com and on the SEC's website at
http://www.sec.gov. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they
are made. The Company undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date they were made, or to
reflect the occurrence of unanticipated events.
Financial Statements
LEMAITRE VASCULAR, INC
(NASDAQ: LMAT) |
|
CONDENSED CONSOLIDATED
BALANCE SHEETS |
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
March 31, 2011 |
December 31,
2010 |
|
(unaudited) |
|
Assets |
|
|
|
|
|
Current assets: |
|
|
Cash and cash equivalents |
$ 19,103 |
$ 22,614 |
Accounts receivable, net |
9,371 |
8,475 |
Inventories |
9,118 |
8,375 |
Other current assets |
3,478 |
3,447 |
|
|
|
Total current assets |
41,070 |
42,911 |
|
|
|
Property and equipment, net |
4,115 |
3,806 |
Goodwill |
11,917 |
11,917 |
Other intangibles, net |
3,458 |
3,686 |
Deferred tax assets |
144 |
134 |
Other assets |
348 |
820 |
|
|
|
Total assets |
$ 61,052 |
$ 63,274 |
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
Current liabilities: |
|
|
Accounts payable |
$ 1,726 |
$ 1,320 |
Accrued expenses |
6,223 |
8,628 |
Acquisition-related
obligations |
268 |
441 |
Total current liabilities |
8,217 |
10,389 |
|
|
|
Deferred tax liabilities |
443 |
443 |
Other long-term liabilities |
82 |
86 |
Total liabilities |
8,742 |
10,918 |
|
|
|
Stockholders' equity |
|
|
Common stock |
161 |
161 |
Additional paid-in capital |
64,921 |
64,642 |
Accumulated deficit |
(8,829) |
(8,583) |
Accumulated other comprehensive loss |
(132) |
(429) |
Less: treasury stock |
(3,811) |
(3,435) |
Total stockholders' equity |
52,310 |
52,356 |
|
|
|
Total liabilities and stockholders'
equity |
$ 61,052 |
$ 63,274 |
|
|
|
|
|
|
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS |
|
|
(amounts in thousands, except per share
amounts) |
|
|
(unaudited) |
|
|
|
|
|
|
For the three
months ended |
|
March 31, 2011 |
March 31, 2010 |
|
|
|
Net sales |
$ 14,598 |
$ 13,815 |
Cost of sales |
4,447 |
3,497 |
|
|
|
Gross profit |
10,151 |
10,318 |
|
|
|
Operating expenses: |
|
|
Sales and marketing |
4,973 |
4,894 |
General and administrative |
2,848 |
2,614 |
Research and development |
1,272 |
1,540 |
Restructuring charges |
1,005 |
-- |
Impairment charge |
83 |
-- |
|
|
|
Total operating expenses |
10,181 |
9,048 |
|
|
|
Income (loss) from operations |
(30) |
1,270 |
|
|
|
Other income: |
|
|
Interest income, net |
1 |
3 |
Other income, net |
147 |
26 |
|
|
|
Total other income, net |
148 |
29 |
|
|
|
Income before income taxes |
118 |
1,299 |
|
|
|
Provision for income taxes |
54 |
278 |
|
|
|
Net income |
$ 64 |
$ 1,021 |
|
|
|
Net income per share of common stock: |
|
|
Basic |
$ -- |
$ 0.07 |
Diluted |
$ -- |
$ 0.06 |
|
|
|
Weighted average shares outstanding: |
|
|
Basic |
15,465 |
15,679 |
Diluted |
16,038 |
16,036 |
Cash dividends declared per common
share |
$ 0.02 |
$ -- |
|
|
|
|
|
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
|
|
SELECTED NET SALES
INFORMATION |
|
|
|
|
(amounts in thousands) |
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
|
March 31,
2011 |
March 31,
2010 |
|
$ |
% |
$ |
% |
Net Sales by Product
Category: |
|
|
|
|
Vascular |
$ 10,760 |
74% |
$ 9,557 |
69% |
Endovascular |
2,901 |
20% |
3,292 |
24% |
Other |
937 |
6% |
966 |
7% |
Total Net Sales |
$ 14,598 |
100% |
$ 13,815 |
100% |
|
|
|
|
|
Net Sales by Geography |
|
|
|
|
Americas |
$ 9,002 |
62% |
$ 8,048 |
58% |
International |
5,596 |
38% |
5,767 |
42% |
Total Net Sales |
$ 14,598 |
100% |
$ 13,815 |
100% |
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC
(NASDAQ: LMAT) |
|
|
|
|
|
|
|
|
IMPACT OF FOREIGN
CURRENCY AND BUSINESS ACTIVITIES |
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
2011 |
2010 |
2009 |
|
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|
|
|
|
|
|
|
|
|
|
Total net sales |
14,598 |
14,431 |
13,656 |
14,158 |
13,815 |
13,584 |
13,346 |
12,630 |
11,348 |
Impact of currency exchange rate fluctuations
(1) |
10 |
(420) |
(418) |
(336) |
314 |
613 |
(215) |
(699) |
(622) |
Net impact of acquisitions, distributed
sales and discontinued products, excluding currency exchange rate
fluctuations (2) |
283 |
56 |
(105) |
(65) |
95 |
397 |
333 |
234 |
101 |
|
|
|
|
|
|
|
|
|
|
(1) Represents the impact of the
change in foreign exchange rates compared to the corresponding
quarter of the prior year based on the weighted averge
exchange |
rate for each quarter. |
|
|
|
|
|
|
|
|
|
(2) Represents the impact of
sales of products of acquired businesses and distributed sales of
other manufacturers' products, net of sales related to
discontinued |
and divested products,
based on 12 months' sales following the date of the event or
transaction, for the current period only. |
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
|
|
NON-GAAP FINANCIAL
MEASURES |
|
|
|
|
(amounts in thousands) |
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP
sales growth: |
|
|
|
|
For the three months ending March 31,
2011 |
|
|
|
|
Net sales as reported |
$ 14,598 |
|
|
|
Impact of currency exchange rate
fluctuations |
(10) |
|
|
|
Net impact of acquisitions, distributed
sales and discontinued products, excluding currency |
(283) |
|
|
|
Adjusted net sales |
|
$ 14,305 |
|
|
|
|
|
|
|
For the three months ending March 31,
2010 |
|
|
|
|
Net Sales as reported |
|
$ 13,815 |
|
|
|
|
|
|
|
Adjusted net sales increase for the
three months ending March 31, 2011 |
|
$ 490 |
4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
|
|
|
|
March 31, 2011 |
March 31, 2010 |
Net Increase $ |
Net Increase % |
Reconciliation between GAAP and
Non-GAAP sales excluding TAArget / Unifit: |
|
|
|
Net sales as reported |
$ 14,598 |
$ 13,815 |
|
|
Less TAArget / Unifit net sales |
(385) |
(789) |
|
|
Adjusted net sales |
$ 14,213 |
$ 13,026 |
$ 1,187 |
9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
|
|
|
|
March 31, 2011 |
March 31, 2010 |
|
|
Reconciliation between GAAP and Non-GAAP
operating expenses: |
|
|
|
|
Operating expenses as reported |
$ 10,181 |
$ 9,048 |
|
|
Restructuring charges |
(1,005) |
-- |
|
|
Impairment |
(83) |
-- |
|
|
|
|
|
|
|
Adjusted operating expenses |
$ 9,093 |
$ 9,048 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
|
|
|
|
March 31, 2011 |
March 31, 2010 |
|
|
Reconciliation between GAAP and
Non-GAAP income (loss) from operations: |
|
|
|
Income (loss) from operations as
reported |
$ (30) |
$ 1,270 |
|
|
Costs associated with manufacturing
transfer |
352 |
-- |
|
|
Restructuring charges |
1,005 |
-- |
|
|
Impairment |
83 |
-- |
|
|
|
|
|
|
|
Adjusted income from operations |
$ 1,410 |
$ 1,270 |
|
|
|
|
|
|
|
CONTACT: J.J. Pellegrino
Chief Financial Officer
LeMaitre Vascular Inc.
781.221.2266 x106
jpellegrino@lemaitre.com
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From May 2024 to Jun 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Jun 2023 to Jun 2024